Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | MTOR | P42345 | 2/20 | 0.90 |
| ▸ | THRB | P10828 | 1/20 | 0.90 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.90 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.90 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL1201153 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL376514 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL28898416 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL458337 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL9007590 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL39902 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL104628 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL6672407 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL29084328 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL2370482 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110614-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4125936-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| CN-113952301-A | Application of medium-chain fatty acid as absorption enhancer to preparation of pharmaceutical composition emulsion | 胡振华 | 2022-01-21 | — | — | CN | claimed |
| WO-2021194890-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| EP-3829565-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | Karlsruher Institut für Technologie (DE) | 2021-06-09 | — | — | EP | claimed |
| WO-2020025488-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | Karlsruher Institut für Technologie (DE) | 2020-02-06 | — | — | WO | claimed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | claimed |
| EP-2428201-A1 | Oral administration of nucleoside monophosphates | Merck Serono S.A. (CH) | 2012-03-14 | — | — | EP | claimed |
| US-12576103-B2 | Heparin and N-acetylcysteine for the treatment of lung injury | ATOSSA THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-113038948-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-118302162-A | Small molecule inhibitors of KRAS muteins | 默沙东有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118267470-A | Anti-SIRP alpha antibodies | 赛罗帕私人有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TIBA BIOTECH LLC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-1996039831-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5484809-A | ANTITUMOR | VESTAR, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0674529-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | NeXstar Pharmaceuticals, Inc. (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5411947-A | converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives; drugs such as AZT, cladribine, AICA-Riboside | VESTAR, INC. (US) | 1995-05-02 | — | — | US | disclosed |
| WO-1994013324-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | VESTAR, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| US-4086417-A | ANTILEUKEMIA | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TLR3, TLR9, TLR6 | LMNA 735/4885MTOR 4666/4885THRB 2308/4885 |
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | LMNA 3032/4885MTOR 1554/4885THRB 4145/4885 |
| US-12576103-B2 | Heparin and N-acetylcysteine for the treatment of lung injury | SERPINC1, TXNRD2, TXN | LMNA 2782/4885MTOR 2194/4885THRB 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.